The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Targeting MET in Lung Cancer: Will Expectations Finally Be MET?
Open accessAbstract
&NA; The hepatocyte growth factor receptor (MET) is a potential therapeutic target in a number of cancers, including NSCLC. In NSCLC, MET pathway activation is thought to occur through a diverse set of mechanisms that influence properties affecting cancer cell survival, growth, and invasiveness. Preclinical and clinical evidence suggests a role for MET activation as both a primary oncogenic driver in subsets of lung cancer and as a secondary driver of acquired resistance to targeted therapy in other genomic subsets. In this review, we explore the biology and clinical significance behind MET proto‐oncogene receptor tyrosine kinase (MET) exon 14 alterations and MET amplification in NSCLC, the role of MET amplification in the setting of acquired resistance to EGFR tyrosine kinase inhibitor therapy in EGFR‐mutant NSCLC, and the history of MET pathway inhibitor drug development in NSCLC, highlighting current strategies that enrich for biomarkers likely to be predictive of response. Whereas previous trials that focused on MET pathway–directed targeted therapy in unselected or MET‐overexpressing NSCLC yielded largely negative results, more recent investigations focusing on MET exon 14 alterations and MET amplification have been notable for meaningful clinical responses to MET inhibitor therapy in a substantial proportion of patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive molecular profiling of lung adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Self-citationSequist, L. V., Yang, J. C.-H., Yamamoto, N., O'Byrne, K., Hirsh, V., Mok, T., Geater, S. L., Orlov, S., Tsai, C.-M., Boyer, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.2806 · Cited by 3,228
First-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer
Solomon, B. J., Mok, T., Kim, D.-W., Wu, Y.-L., Nakagawa, K., Mekhail, T., Felip, E., Cappuzzo, F., Paolini, J., Usari, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408440 · Cited by 3,190
Self-citationYu, H. A., Arcila, M. E., Rekhtman, N., Sima, C. S., Zakowski, M. F., Pao, W., Kris, M. G., Miller, V. A., Ladanyi, M., & Riely, G. J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2246 · Cited by 2,454
Frampton, G. M., Fichtenholtz, A., Otto, G. A., Wang, K., Downing, S. R., He, J., Schnall-Levin, M., White, J., Sanford, E. M., An, P., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2696 · Cited by 2,157 · cited 2×
“tested positive for amplification of other genes such as ERBB2 by FISH.(50,51) As with FISH, copy number gains detected by NGS are reported as continuous variables,”
MethodMemorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)
Cheng, D. T., Mitchell, T. N., Zehir, A., Shah, R. H., Benayed, R., Syed, A., Chandramohan, R., Liu, Z. Y., Won, H. H., Scott, S. N., et al. (2015) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2014.12.006 · Cited by 2,119
Thress, K. S., Paweletz, C. P., Felip, E., Cho, B. C., Stetson, D., Dougherty, B., Lai, Z., Markovets, A., Vivancos, A., Kuang, Y., et al. (2015) · Nature Medicine · doi:10.1038/nm.3854 · Cited by 1,589
Schmidt, L., Duh, F.-M., Chen, F., Kishida, T., Glenn, G., Choyke, P., Scherer, S. W., Zhuang, Z., Lubensky, I., Dean, M., et al. (1997) · Nature Genetics · doi:10.1038/ng0597-68 · Cited by 1,524
Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC
Turke, A. B., Zejnullahu, K., Wu, Y.-L., Song, Y., Dias-Santagata, D., Lifshits, E., Toschi, L., Rogers, A., Mok, T., Sequist, L., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.11.022 · Cited by 1,059
The landscape of kinase fusions in cancer
Stransky, N., Cerami, E., Schalm, S., Kim, J. L., & Lengauer, C. (2014) · Nature Communications · doi:10.1038/ncomms5846 · Cited by 968
Anchored multiplex PCR for targeted next-generation sequencing
Zheng, Z., Liebers, M., Zhelyazkova, B., Cao, Y., Panditi, D., Lynch, K. D., Chen, J., Robinson, H. E., Shim, H. S., Chmielecki, J., et al. (2014) · Nature Medicine · doi:10.1038/nm.3729 · Cited by 915
An overview of the c-MET signaling pathway
Organ, S. L., & Tsao, M.-S. (2011) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834011422556 · Cited by 875
Drug development of MET inhibitors: targeting oncogene addiction and expedience
Comoglio, P. M., Giordano, S., & Trusolino, L. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2530 · Cited by 818
Chromosome aberrations in solid tumors
Albertson, D. G., Collins, C., McCormick, F., & Gray, J. W. (2003) · Nature Genetics · doi:10.1038/ng1215 · Cited by 812
Frampton, G. M., Ali, S. M., Rosenzweig, M., Chmielecki, J., Lu, X., Bauer, T. M., Akimov, M., Bufill, J. A., Lee, C., Jentz, D., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0285 · Cited by 796 · cited 4×
“The reported prevalence of de novo MET amplification in NSCLC ranges from 1% to 5%, depending on the level of preselection, the assay, and the positivity cutpoint used (see Table 1).(27,29,35,36,53) In adenocarcinoma, because most true oncogenic drivers are mutually exclusive, so-called oncogene overlap analysis was u…”
BackgroundMethodInfluentialSelf-citationAwad, M. M., Oxnard, G. R., Jackman, D. M., Savukoski, D. O., Hall, D., Shivdasani, P., Heng, J. C., Dahlberg, S. E., Jänne, P. A., Verma, S., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.4600 · Cited by 693
Ma, P. C., Jagadeeswaran, R., Jagadeesh, S., Tretiakova, M. S., Nallasura, V., Fox, E. A., Hansen, M., Schaefer, E., Naoki, K., Lader, A., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2650 · Cited by 576
Paik, P. K., Drilon, A., Fan, P.-D., Yu, H., Rekhtman, N., Ginsberg, M. S., Borsu, L., Schultz, N., Berger, M. F., Rudin, C. M., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1467 · Cited by 575
Self-citationCappuzzo, F., Marchetti, A., Skokan, M., Rossi, E., Gajapathy, S., Felicioni, L., del Grammastro, M., Sciarrotta, M. G., Buttitta, F., Incarbone, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.1635 · Cited by 557
Self-citationSomatic Mutations Lead to an Oncogenic Deletion of Met in Lung Cancer
Kong-Beltran, M., Seshagiri, S., Zha, J., Zhu, W., Bhawe, K., Mendoza, N., Holcomb, T., Pujara, K., Stinson, J., Fu, L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2749 · Cited by 490
Spigel, D. R., Ervin, T. J., Ramlau, R. A., Daniel, D. B., Goldschmidt, J. H., Blumenschein, G. R., Krzakowski, M. J., Robinet, G., Godbert, B., Barlesi, F., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.4189 · Cited by 480
ALK in Lung Cancer: Past, Present, and Future
Shaw, A. T., & Engelman, J. A. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.5353 · Cited by 461
Peschard, P., Fournier, T. M., Lamorte, L., Naujokas, M. A., Band, H., Langdon, W. Y., & Park, M. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00378-1 · Cited by 460
Ma, P. C., Kijima, T., Maulik, G., Fox, E. A., Sattler, M., Griffin, J. D., Johnson, B. E., & Salgia, R. (2003) · PubMed · Cited by 454
Tong, J. H., Yeung, S. F., Chan, A. W. H., Chung, L. Y., Chau, S. L., Lung, R. W. M., Tong, C. Y., Chow, C., Tin, E. K. Y., Yu, Y. H., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2061 · Cited by 449
Ou, S.-H. I., Kwak, E. L., Siwak-Tapp, C., Dy, J., Bergethon, K., Clark, J. W., Camidge, D. R., Solomon, B. J., Maki, R. G., Bang, Y.-J., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31821528d3 · Cited by 432
Self-citationLiu, X., Jia, Y., Stoopler, M. B., Shen, Y., Cheng, H., Chen, J., Mansukhani, M., Koul, S., Halmos, B., & Borczuk, A. C. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.0674 · Cited by 349
Onozato, R., Kosaka, T., Kuwano, H., Sekido, Y., Yatabe, Y., & Mitsudomi, T. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181913e0e · Cited by 327
EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients
Planchard, D., Loriot, Y., André, F., Gobert, A., Auger, N., Lacroix, L., & Soria, J. C. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv319 · Cited by 311
Expression and mutational analysis of MET in human solid cancers
Ma, P. C., Tretiakova, M. S., MacKinnon, A. C., Ramnath, N., Johnson, C., Dietrich, S., Seiwert, T., Christensen, J. G., Jagadeeswaran, R., Krausz, T., et al. (2008) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.20604 · Cited by 300
A role for common fragile site induction in amplification of human oncogenes
Hellman, A., Zlotorynski, E., Scherer, S. W., Cheung, J., Vincent, J. B., Smith, D. I., Trakhtenbrot, L., & Kerem, B. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00017-x · Cited by 300
Wang, R., Ferrell, L. D., Faouzi, S., Maher, J. J., & Bishop, J. M. (2001) · The Journal of Cell Biology · doi:10.1083/jcb.153.5.1023 · Cited by 281
Scagliotti, G., von Pawel, J., Novello, S., Ramlau, R., Favaretto, A., Barlesi, F., Akerley, W., Orlov, S., Santoro, A., Spigel, D., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.7317 · Cited by 265
Camidge, D. R., Ou, S.-H. I., Shapiro, G., Otterson, G. A., Villaruz, L. C., Villalona-Calero, M. A., Iafrate, A. J., Varella-Garcia, M., Dacic, S., Cardarella, S., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.8001 · Cited by 256
Self-citationDurable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer
Farago, A. F., Le, L. P., Zheng, Z., Muzikansky, A., Drilon, A., Patel, M., Bauer, T. M., Liu, S. V., Ou, S.-H. I., Jackman, D., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/01.jto.0000473485.38553.f0 · Cited by 229
Self-citationCytotoxic Activity of Tivantinib (ARQ 197) Is Not Due Solely to c-MET Inhibition
Katayama, R., Aoyama, A., Yamori, T., Qi, J., Oh-hara, T., Song, Y., Engelman, J. A., & Fujita, N. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3256 · Cited by 213
Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancer
Puri, N., & Salgia, R. (2008) · Journal of Carcinogenesis · doi:10.4103/1477-3163.44372 · Cited by 211
The Sema domain of Met is necessary for receptor dimerization and activation
Kong-Beltran, M., Stamos, J., & Wickramasinghe, D. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.013 · Cited by 209
Targeting Receptor Tyrosine Kinase MET in Cancer: Small Molecule Inhibitors and Clinical Progress
Cui, J. J. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401427c · Cited by 209
Ichimura, E., Maeshima, A., Nakajima, T., & Nakamura, T. (1996) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1996.tb03111.x · Cited by 201
Met gene copy number predicts the prognosis for completely resected non‐small cell lung cancer
Okuda, K., Sasaki, H., Yukiue, H., Yano, M., & Fujii, Y. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00916.x · Cited by 198
Ethnic Differences and Functional Analysis of MET Mutations in Lung Cancer
Krishnaswamy, S., Kanteti, R., Duke-Cohan, J. S., Loganathan, S., Liu, W., Ma, P. C., Sattler, M., Singleton, P. A., Ramnath, N., Innocenti, F., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0070 · Cited by 184
Noonan, S. A., Berry, L., Lu, X., Gao, D., Barón, A. E., Chesnut, P., Sheren, J., Aisner, D. L., Merrick, D., Doebele, R. C., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.04.033 · Cited by 173
Self-citationAcquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping
Heist, R. S., Sequist, L. V., Borger, D., Gainor, J. F., Arellano, R. S., Le, L. P., Dias-Santagata, D., Clark, J. W., Engelman, J. A., Shaw, A. T., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.06.013 · Cited by 169
High MET copy number and MET overexpression: poor outcome in non-small cell lung cancer patients.
Park, S., Choi, Y., Sung, C. O., An, J., Seo, J., Ahn, M., Ahn, J. S., Park, K., Shin, Y. K., Erkin, Ö. C., et al. (2012) · PubMed · doi:10.14670/hh-27.197 · Cited by 158
c-MET/Phospho-MET Protein Expression and MET Gene Copy Number in Non-small Cell Lung Carcinomas
Tsuta, K., Kozu, Y., Mimae, T., Yoshida, A., Kohno, T., Sekine, I., Tamura, T., Asamura, H., Furuta, K., & Tsuda, H. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318241655f · Cited by 152
MET Overexpression Turns Human Primary Osteoblasts into Osteosarcomas
Patanè, S., Avnet, S., Coltella, N., Costa, B., Sponza, S., Olivero, M., Vigna, E., Naldini, L., Baldini, N., Ferracini, R., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4422 · Cited by 132
Yoshioka, H., Azuma, K., Yamamoto, N., Takahashi, T., Nishio, M., Katakami, N., Ahn, M., Hirashima, T., Maemondo, M., Kim, S. W., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv288 · Cited by 123
Drilon, A. E. D. C., Camidge, D. R., Ou, S. I., Clark, J. W., Socinski, M. A., Weiss, J. M., Riely, G. J., Winter, M., Wang, S. C., Monti, K. L., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.108 · Cited by 119
Self-citationTargeting MET Amplification as a New Oncogenic Driver
Kawakami, H., Okamoto, I., Okamoto, W., Tanizaki, J., Nakagawa, K., & Nishio, K. (2014) · Cancers · doi:10.3390/cancers6031540 · Cited by 107
Response to Crizotinib in a Patient With Lung Adenocarcinoma Harboring a MET Splice Site Mutation
Jenkins, R. W., Oxnard, G. R., Elkin, S. K., Sullivan, E. K., Carter, J. L., & Barbie, D. A. (2015) · Clinical Lung Cancer · doi:10.1016/j.cllc.2015.01.009 · Cited by 104
Liu, Y. (1998) · Gene · doi:10.1016/s0378-1119(98)00264-9 · Cited by 89
MET Mutation Associated with Responsiveness to Crizotinib
Waqar, S. N., Morgensztern, D., & Sehn, J. K. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000478 · Cited by 83
Jorge, S. E., Schulman, S., Freed, J. A., VanderLaan, P. A., Rangachari, D., Kobayashi, S. S., Huberman, M. S., & Costa, D. B. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.10.028 · Cited by 82
Tanaka, A., Sueoka‐Aragane, N., Nakamura, T., Takeda, Y., Mitsuoka, M., Yamasaki, F., Hayashi, S., Sueoka, E., & Kimura, S. H. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.06.004 · Cited by 67
The c-Met Inhibitor MSC2156119J Effectively Inhibits Tumor Growth in Liver Cancer Models
Bladt, F., Friese‐Hamim, M., Ihling, C. H., Wilm, C., & Blaukat, A. (2014) · Cancers · doi:10.3390/cancers6031736 · Cited by 64
MET-Mutated NSCLC with Major Response to Crizotinib
Mendenhall, M. A., & Goldman, J. W. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000491 · Cited by 60
Prognostic and predictive value of MET deregulation in non-small cell lung cancer.
Finocchiaro, G., Toschi, L., Gianoncelli, L., Baretti, M., & Santoro, A. (2015) · PubMed · doi:10.3978/j.issn.2305-5839.2015.03.43 · Cited by 58
Dimou, A., Non, L. R., Chae, Y. K., Tester, W. J., & Syrigos, K. N. (2014) · PLoS ONE · doi:10.1371/journal.pone.0107677 · Cited by 56
Matsubara, D., Ishikawa, S., Oguni, S., Aburatani, H., Fukayama, M., & Niki, T. (2010) · American Journal Of Pathology · doi:10.2353/ajpath.2010.100217 · Cited by 53
Tsao, M., Yang, Y., Marcus, A., Liu, G., & Mou, L.-J. (2001) · Human Pathology · doi:10.1053/hupa.2001.21133 · Cited by 52
Lee, C. B., Usenko, D., Frampton, G. M., McMahon, C., Ali, S. M., & Weiss, J. M. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000645 · Cited by 45
Wu, Y.-L. L. C., Yang, J. C., Kim, D., Su, W., Ahn, M., Lee, K. H., Vansteenkiste, J., Zhang, L., Felip, E., Peng, B., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.8017 · Cited by 44
Camidge, D. R., Morán, T., Demedts, I., Grosch, H., Mileham, K. F., Molina, J. R., Juan, Ó., Bepler, G., Goldman, J. W., Park, K., et al. (2022) · Clinical Lung Cancer · doi:10.1016/j.cllc.2022.03.003 · Cited by 27
Self-citationMahjoubi, L., Gazzah, A., Besse, B., Lacroix, L., & Soria, J. (2016) · Investigational New Drugs · doi:10.1007/s10637-016-0332-0 · Cited by 23
Frampton, G. M., Ali, S. M., Rosenzweig, M. R., Goldman, J. W., Lee, C. B., Weiss, J., Bufill, J. A., Salgia, R., Jahanzeb, M., Konduri, K., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.11007 · Cited by 5
Self-citation
Cited by
Thai, A. A., Solomon, B. J., Sequist, L. V., Gainor, J. F., & Heist, R. S. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00312-3 · Cited by 2,576
Comprehensive review of targeted therapy for colorectal cancer
Xie, Y.-H., Chen, Y.-X., & Fang, J.-Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0116-z · Cited by 1,687
Toward personalized treatment approaches for non-small-cell lung cancer
Wang, M., Herbst, R. S., & Boshoff, C. (2021) · Nature Medicine · doi:10.1038/s41591-021-01450-2 · Cited by 1,093
Understanding and targeting resistance mechanisms in NSCLC
Rotow, J., & Bivona, T. G. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.84 · Cited by 972
Regulation of PD-L1 expression in the tumor microenvironment
Yi, M., Niu, M., Xu, L., Luo, S., & Wu, K. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-01027-5 · Cited by 681
Metadata
- Authors
- Drilon, A., Cappuzzo, F., Ou, S.-H. I., & Camidge, D. R.
- Venue
- Journal of Thoracic Oncology
- Publisher
- Elsevier BV
- Published
- 2017-01
- Volume
- 12
- Issue
- 1
- Pages
- 15-26
- ISSN
- 1556-0864 (ISSN-L)
- OpenAlex
- W2544185683
- Cited by
- 389
- References
- 67
- FWCI
- 23.57
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.